ARX-Aroa Biosurgery

[Crackity]

Hardly a success story.
When ARX listed approx five/six years ago the share price was $1.40 plus.
Today it is 66 cents.

The company is definitely a success.

Bound to be some unhappy IPO shareholders I reckon

[Shareguy]

Hardly a success story.
When ARX listed approx five/six years ago the share price was $1.40 plus.
Today it is 66 cents.

Gosh I call sales of over $100m in annual sales from sheep's waste products virtually all exported from NZ pretty good. Aroa have had 5 years of consistent sales growth with the current year forecast also positive.  The foot ulcer market looks massive.

As far as the share price goes it's anyone's guess. I'm well up on what I paid and have no plans to sell.

[Crackity]

Finally, we established new positions in each of Energy One (repurchasing a small position having previously been invested), Kiwi med-tech success story Aroa Biosurgery, and investment platform operator Praemium. As with EDU, Pureprofile, and Verbrec, these three companies couldn't be more different from each other fundamentally. But likewise, each share interesting attributes that we value highly. Each has a strong underlying business with high-quality revenues, meaningful growth opportunities ahead, strong operational execution, and disciplined capital management. Each has the potential of being considerably larger businesses in the future, and are generating positive cashflow so can self-fund that growth. As their respective growth stories continue to play out, each holds the potential for valuation re-rates from current levels.

DMX July report from Noodles and co